MA50657A - Formulations de niraparib - Google Patents
Formulations de niraparibInfo
- Publication number
- MA50657A MA50657A MA050657A MA50657A MA50657A MA 50657 A MA50657 A MA 50657A MA 050657 A MA050657 A MA 050657A MA 50657 A MA50657 A MA 50657A MA 50657 A MA50657 A MA 50657A
- Authority
- MA
- Morocco
- Prior art keywords
- niraparib formulations
- niraparib
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563535P | 2017-09-26 | 2017-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50657A true MA50657A (fr) | 2020-08-05 |
Family
ID=63858161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050657A MA50657A (fr) | 2017-09-26 | 2018-09-26 | Formulations de niraparib |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11730725B2 (fr) |
| EP (1) | EP3687505A1 (fr) |
| JP (1) | JP7269227B2 (fr) |
| KR (1) | KR20200058496A (fr) |
| CN (1) | CN111278433A (fr) |
| AU (2) | AU2018341479B2 (fr) |
| BR (1) | BR112020006039A2 (fr) |
| CA (1) | CA3076907A1 (fr) |
| CL (1) | CL2020000747A1 (fr) |
| EA (1) | EA202090573A1 (fr) |
| IL (1) | IL273282A (fr) |
| MA (1) | MA50657A (fr) |
| MX (1) | MX2020003760A (fr) |
| PH (1) | PH12020550341A1 (fr) |
| SG (1) | SG11202002113TA (fr) |
| TW (1) | TW201927304A (fr) |
| WO (1) | WO2019067634A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201992177A1 (ru) | 2017-03-27 | 2020-02-25 | Тесаро, Инк. | Композиции на основе нирапариба |
| ES2926255T3 (es) | 2017-04-24 | 2022-10-24 | Tesaro Inc | Métodos de fabricación de niraparib |
| JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ， インコーポレイテッド | 癌を処置する併用療法 |
| TW201927304A (zh) | 2017-09-26 | 2019-07-16 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| EP4146209A1 (fr) * | 2020-05-08 | 2023-03-15 | JANSSEN Pharmaceutica NV | Traitements du cancer de la prostate au moyen d'associations d'acétate d'abiratérone et de niraparib |
| BR112022024533A2 (pt) * | 2020-06-19 | 2022-12-27 | Glaxosmithkline Ip No 2 Ltd | Formulação compreendendo daprodustat |
| CA3199341A1 (fr) * | 2020-11-20 | 2022-05-27 | Nikolaos DRAKOULIS | Formulation de chlorure d'ammonium d'aide a la defense naturelle humaine contre des virus |
| WO2023159066A1 (fr) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Utilisation de niraparib pour le traitement du cancer du cerveau |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606337D0 (en) | 1996-03-26 | 1996-05-29 | Freeman Reginald E | Rheometer |
| AR030630A1 (es) | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
| BRPI0516435B1 (pt) | 2004-10-29 | 2021-09-21 | Kalypsys , Inc | Composto, e composição farmacêutica |
| GB0700432D0 (en) | 2007-01-10 | 2007-02-21 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AU2007232297B2 (en) | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
| GB0606663D0 (en) | 2006-04-03 | 2006-05-10 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008043024A2 (fr) * | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Formulation pharmaceutique orale comprenant un sulfonyle bicyclique modulateur de ppar pour le traitement d'une maladie |
| PL2336120T3 (pl) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP) |
| CN101668561A (zh) | 2007-01-16 | 2010-03-10 | 彼帕科学公司 | 癌症治疗制剂 |
| WO2009050469A1 (fr) | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | 4-[3-(4-cyclopropanecarbonylpipérazin-1-carbonyl)-4-fluorobenzyl]-2h-phtalazin-1-one |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| WO2011028580A1 (fr) | 2009-08-26 | 2011-03-10 | Cephalon, Inc. | Nouvelles formes d'un composé multicyclique |
| CA2779052A1 (fr) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Composition pharmaceutique d'antecavir et processus de fabrication |
| EP2928473B1 (fr) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Arylation n-2 régiosélective d'indazoles |
| PT2928865T (pt) | 2012-12-07 | 2018-06-11 | Merck Sharp & Dohme | Processo de transaminação biocatalítica |
| EP2983674A4 (fr) * | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale |
| MX2015015037A (es) | 2013-05-02 | 2016-07-08 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). |
| US9191894B2 (en) | 2013-07-23 | 2015-11-17 | Disney Enterprises, Inc. | Power saving for multi-hop communications |
| ES2700348T3 (es) * | 2014-01-05 | 2019-02-15 | Univ Washington | Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos |
| WO2015164161A1 (fr) | 2014-04-22 | 2015-10-29 | Calitor Sciences, Llc | Composés pyrazolone bicycliques et procédés d'utilisation |
| US9987275B2 (en) | 2014-04-23 | 2018-06-05 | The Brigham And Women's Hospital, Inc. | Targeting PARP1 for treatment of TSC and cancers |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| WO2016028689A1 (fr) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Comprimés de rucaparib à dosage élevé |
| WO2016094391A1 (fr) | 2014-12-08 | 2016-06-16 | Myriad Genetics, Inc. | Méthodes et matériaux permettant de prédire une réaction au niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TW202315634A (zh) | 2015-03-03 | 2023-04-16 | 美商製藥公司 | 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物 |
| MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| SG11201707989PA (en) | 2015-04-06 | 2017-10-30 | Janssen Pharmaceutica Nv | Compositions containing ibrutinib |
| SI3613745T1 (sl) | 2015-07-02 | 2021-12-31 | Acerta Pharma B.V. | Trdne oblike in formulacije (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin- 2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida |
| US10660954B2 (en) | 2015-07-31 | 2020-05-26 | University Of Florida Research Foundation, Incorporated | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
| CA3008338A1 (fr) | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprenant un inhibiteur de btk |
| US20190133980A1 (en) | 2016-06-02 | 2019-05-09 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
| NZ749413A (en) | 2016-06-29 | 2023-05-26 | Tesaro Inc | Methods of treating ovarian cancer |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| SG11201903835WA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against programmed death- 1 (pd-1) |
| JP2019537438A (ja) | 2016-11-01 | 2019-12-26 | アナプティスバイオ インコーポレイティッド | Ｔｉｍ−３（ｔ細胞イムノグロブリンおよびムチンタンパク質３）に対する抗体 |
| CN106831708A (zh) | 2016-11-22 | 2017-06-13 | 西安泰科迈医药科技股份有限公司 | 一种新型口服抗癌药物Nirapairb的合成方法 |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| CN106854176A (zh) | 2016-12-21 | 2017-06-16 | 南京艾德凯腾生物医药有限责任公司 | 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法 |
| WO2018122168A1 (fr) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp |
| WO2018129559A1 (fr) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 |
| MA47206A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
| EA201992177A1 (ru) | 2017-03-27 | 2020-02-25 | Тесаро, Инк. | Композиции на основе нирапариба |
| MX2019011491A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Formulaciones de niraparib. |
| ES2926255T3 (es) | 2017-04-24 | 2022-10-24 | Tesaro Inc | Métodos de fabricación de niraparib |
| CA3059468A1 (fr) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Agents anticorps diriges contre la proteine codee par le gene d'activation des lymphocytes 3 (lag-3) et utilisations associees |
| BR112019023591A2 (pt) | 2017-05-09 | 2020-05-26 | Tesaro, Inc. | Terapias de combinação para tratar câncer |
| JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ， インコーポレイテッド | 癌を処置する併用療法 |
| CN108530425A (zh) | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| TW201927304A (zh) | 2017-09-26 | 2019-07-16 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| SG11202006147SA (en) | 2017-12-27 | 2020-07-29 | Tesaro Inc | Methods of treating cancer |
| SG11202007420PA (en) | 2018-02-05 | 2020-09-29 | Tesaro Inc | Pediatric niraparib formulations and pediatric treatment methods |
-
2018
- 2018-09-26 TW TW107133873A patent/TW201927304A/zh unknown
- 2018-09-26 MA MA050657A patent/MA50657A/fr unknown
- 2018-09-26 US US16/650,948 patent/US11730725B2/en active Active
- 2018-09-26 EP EP18786585.2A patent/EP3687505A1/fr active Pending
- 2018-09-26 EA EA202090573A patent/EA202090573A1/ru unknown
- 2018-09-26 CA CA3076907A patent/CA3076907A1/fr active Pending
- 2018-09-26 CN CN201880062593.0A patent/CN111278433A/zh active Pending
- 2018-09-26 JP JP2020517352A patent/JP7269227B2/ja active Active
- 2018-09-26 KR KR1020207011938A patent/KR20200058496A/ko not_active Application Discontinuation
- 2018-09-26 BR BR112020006039-9A patent/BR112020006039A2/pt unknown
- 2018-09-26 WO PCT/US2018/052979 patent/WO2019067634A1/fr unknown
- 2018-09-26 AU AU2018341479A patent/AU2018341479B2/en active Active
- 2018-09-26 SG SG11202002113TA patent/SG11202002113TA/en unknown
- 2018-09-26 MX MX2020003760A patent/MX2020003760A/es unknown
-
2020
- 2020-03-12 IL IL273282A patent/IL273282A/en unknown
- 2020-03-23 CL CL2020000747A patent/CL2020000747A1/es unknown
- 2020-03-26 PH PH12020550341A patent/PH12020550341A1/en unknown
-
2022
- 2022-01-27 AU AU2022200520A patent/AU2022200520A1/en not_active Abandoned
-
2023
- 2023-06-23 US US18/340,467 patent/US20240082231A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020003760A (es) | 2020-07-29 |
| AU2018341479A1 (en) | 2020-04-16 |
| US11730725B2 (en) | 2023-08-22 |
| US20240082231A1 (en) | 2024-03-14 |
| AU2022200520A1 (en) | 2022-02-17 |
| IL273282A (en) | 2020-04-30 |
| SG11202002113TA (en) | 2020-04-29 |
| US20200289494A1 (en) | 2020-09-17 |
| EA202090573A1 (ru) | 2020-09-07 |
| TW201927304A (zh) | 2019-07-16 |
| AU2018341479B2 (en) | 2022-02-17 |
| JP7269227B2 (ja) | 2023-05-08 |
| CN111278433A (zh) | 2020-06-12 |
| PH12020550341A1 (en) | 2021-02-15 |
| EP3687505A1 (fr) | 2020-08-05 |
| JP2020535158A (ja) | 2020-12-03 |
| WO2019067634A1 (fr) | 2019-04-04 |
| CL2020000747A1 (es) | 2020-09-25 |
| KR20200058496A (ko) | 2020-05-27 |
| CA3076907A1 (fr) | 2019-04-04 |
| BR112020006039A2 (pt) | 2020-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3731771T3 (da) | V462033dk00 | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| MA50657A (fr) | Formulations de niraparib | |
| CL2018000524S1 (es) | Golilla | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| DK3568655T3 (da) | Rekuperator | |
| DK3651736T3 (da) | Langtidsvirkende formuleringer | |
| DK3571580T5 (da) | Load-logical-and-shift-guarded-instruktion | |
| DK3612237T3 (da) | Genterapi | |
| DK3568506T3 (da) | Offeranode | |
| MA50068A (fr) | Formulations de copanlisib | |
| DK3576686T3 (da) | Brokbind | |
| DK3676276T3 (da) | Spirothietannukleosider | |
| DK3576718T3 (da) | Pastil | |
| FI11704U1 (fi) | Liittopuujärjestely | |
| TR201503831A2 (tr) | Antimipertansif kombinasyon formülasyonları | |
| DK3510051T3 (da) | Carboxylalkylchitosan | |
| DK3395159T3 (da) | Ballepresse | |
| ES1205411Y (es) | Maleta-Gaveta | |
| ES1198359Y (es) | Columbario | |
| FI11529U1 (fi) | Ontelolaatan kannake | |
| DK3645955T3 (da) | Buffertank | |
| DK3401461T3 (da) | Falsetagtegl | |
| DK3391735T3 (da) | Ballepresse | |
| DK3391733T3 (da) | Ballepresse |